董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mario Eisenberger | 男 | Director | 73 | 39.17万美元 | 1.50 | 2023-01-27 |
| Harry Fisch | 男 | Director,Vice Chairman of the Board,Chief Corporate Officer | 64 | 316.20万美元 | 803.94 | 2023-01-27 |
| Michael L. Rankowitz | 男 | Director | 65 | 39.17万美元 | 未持股 | 2023-01-27 |
| Grace Hyun | 女 | Director | 51 | 32.53万美元 | 未持股 | 2023-01-27 |
| Mitchell S. Steiner | 男 | President and Chief Executive Officer and Director,Chairman of the Board | 62 | 609.63万美元 | 827.99 | 2023-01-27 |
| Lucy Lu | 女 | Director | 49 | 39.17万美元 | 2.00 | 2023-01-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Harry Fisch | 男 | Director,Vice Chairman of the Board,Chief Corporate Officer | 64 | 316.20万美元 | 803.94 | 2023-01-27 |
| K. Gary Barnette | 男 | Chief Scientific Officer | 55 | 336.62万美元 | 未持股 | 2023-01-27 |
| Mitchell S. Steiner | 男 | President and Chief Executive Officer and Director,Chairman of the Board | 62 | 609.63万美元 | 827.99 | 2023-01-27 |
| Michele Greco | 女 | Chief Financial Officer and Chief Administrative Officer | 64 | 83.57万美元 | 21.47 | 2023-01-27 |
董事简历
中英对照 | 中文 | 英文- Mario Eisenberger
-
Mario Eisenberger自2016年10月起担任公司董事。Eisenberger博士目前是约翰霍普金斯大学（Johns Hopkins University）的Dale Hughes肿瘤学教授，自1993年以来一直担任全职教员。从2010年到2014年，Eisenberger博士创立了Oncology Trials Insights，Inc.，这是一家私人持有的临床试验管理公司。自2010年以来，Eisenberger博士还担任FDA肿瘤药物咨询委员会的临时成员。1988年以来，他曾一直任职咨询、战略和数据安全监控委员会，包括Bristol-Myers Squibb公司、Sanofi公司、Astellas公司、Schering Plough公司、Auguron公司、Akzo公司、杜邦公司、Rhone-Poulenc Rorer公司、Aventis公司、Jansen公司、IPSEN公司、Active Biotech公司、Medivation公司、Tokai公司、Xanthus公司、Cytogen公司、Ortho Biotech公司、Merck-Sharp公司和Dohme公司、Tyme公司、Ferring公司和Bayer公司。Eisenberger从1984年到1998年担任Southwest Oncology Group高级前列腺癌委员会主管和泌尿生殖系统癌症副主席。从1984年到1993年，他曾担任the University of Maryland的肿瘤学教授。从1984年到1989年，他曾担任the Baltimore Vah的肿瘤首席。从1982年到1984年，他曾担任the National Institute的癌症治疗评估项目的高级研究员，负责协调泌尿系统癌症的壁外临床研究。从1976年到1982年，他曾任职迈阿密大学（the University of Miami）的教员。Eisenberger博士于1972年在巴西里约热内卢联邦大学（Federal University of Rio de Janeiro Brazil）获得医学博士学位，并获得内科和医学肿瘤学的董事会认证。
Mario Eisenberger,has served as a director of the Company since October 2016. Dr. Eisenberger currently is the Dale Hughes Professor of Oncology at The Johns Hopkins University and has been in the full-time faculty since 1993. From 2010 to 2014, Dr. Eisenberger founded Oncology Trials Insights, Inc., a privately held clinical trials management company. Since 2010, Dr. Eisenberger has also served as an ad-hoc member of the Oncologic Drugs Advisory Committee of the FDA. Since 1988, he has served in advisory, strategic and data safety monitoring boards, including Bristol-Myers Squibb, Sanofi, Astellas, Schering Plough, Auguron, AKZO, Dupont, Rhone-Poulenc Rorer, Aventis, Jansen, Ipsen, Active Biotech, Medivation, Tokai, Xanthus, Cytogen, Ortho Biotech, Merck-Sharp and Dohme, Tyme, Inc., Ferring and Bayer. From 1984 to 1998, Dr. Eisenberger held the position of head of the advanced prostate cancer committee and vice chair of the genitourinary cancer of the Southwest Oncology Group. From 1984 to 1993, he served as Professor of Oncology at The University of Maryland. From 1984 to 1989, he was the Chief of Oncology at the Baltimore VAH. From 1982 to 1984, he was a Senior Investigator at the Cancer Therapy Evaluation Program of the National Institute in charge of coordinating extramural clinical research in urological cancers. From 1976 to 1982, he served in the faculty of the University of Miami. Dr. Eisenberger obtained his M.D. at the Federal University of Rio de Janeiro Brazil in 1972 and is board certified in Internal Medicine and Medical Oncology. - Mario Eisenberger自2016年10月起担任公司董事。Eisenberger博士目前是约翰霍普金斯大学（Johns Hopkins University）的Dale Hughes肿瘤学教授，自1993年以来一直担任全职教员。从2010年到2014年，Eisenberger博士创立了Oncology Trials Insights，Inc.，这是一家私人持有的临床试验管理公司。自2010年以来，Eisenberger博士还担任FDA肿瘤药物咨询委员会的临时成员。1988年以来，他曾一直任职咨询、战略和数据安全监控委员会，包括Bristol-Myers Squibb公司、Sanofi公司、Astellas公司、Schering Plough公司、Auguron公司、Akzo公司、杜邦公司、Rhone-Poulenc Rorer公司、Aventis公司、Jansen公司、IPSEN公司、Active Biotech公司、Medivation公司、Tokai公司、Xanthus公司、Cytogen公司、Ortho Biotech公司、Merck-Sharp公司和Dohme公司、Tyme公司、Ferring公司和Bayer公司。Eisenberger从1984年到1998年担任Southwest Oncology Group高级前列腺癌委员会主管和泌尿生殖系统癌症副主席。从1984年到1993年，他曾担任the University of Maryland的肿瘤学教授。从1984年到1989年，他曾担任the Baltimore Vah的肿瘤首席。从1982年到1984年，他曾担任the National Institute的癌症治疗评估项目的高级研究员，负责协调泌尿系统癌症的壁外临床研究。从1976年到1982年，他曾任职迈阿密大学（the University of Miami）的教员。Eisenberger博士于1972年在巴西里约热内卢联邦大学（Federal University of Rio de Janeiro Brazil）获得医学博士学位，并获得内科和医学肿瘤学的董事会认证。
- Mario Eisenberger,has served as a director of the Company since October 2016. Dr. Eisenberger currently is the Dale Hughes Professor of Oncology at The Johns Hopkins University and has been in the full-time faculty since 1993. From 2010 to 2014, Dr. Eisenberger founded Oncology Trials Insights, Inc., a privately held clinical trials management company. Since 2010, Dr. Eisenberger has also served as an ad-hoc member of the Oncologic Drugs Advisory Committee of the FDA. Since 1988, he has served in advisory, strategic and data safety monitoring boards, including Bristol-Myers Squibb, Sanofi, Astellas, Schering Plough, Auguron, AKZO, Dupont, Rhone-Poulenc Rorer, Aventis, Jansen, Ipsen, Active Biotech, Medivation, Tokai, Xanthus, Cytogen, Ortho Biotech, Merck-Sharp and Dohme, Tyme, Inc., Ferring and Bayer. From 1984 to 1998, Dr. Eisenberger held the position of head of the advanced prostate cancer committee and vice chair of the genitourinary cancer of the Southwest Oncology Group. From 1984 to 1993, he served as Professor of Oncology at The University of Maryland. From 1984 to 1989, he was the Chief of Oncology at the Baltimore VAH. From 1982 to 1984, he was a Senior Investigator at the Cancer Therapy Evaluation Program of the National Institute in charge of coordinating extramural clinical research in urological cancers. From 1976 to 1982, he served in the faculty of the University of Miami. Dr. Eisenberger obtained his M.D. at the Federal University of Rio de Janeiro Brazil in 1972 and is board certified in Internal Medicine and Medical Oncology.
- Harry Fisch
-
Harry Fisch，他是公司的董事（2016年10月以来）。他曾担任Aspen Park的联席创始人，也曾担任Aspen Park的董事会主席兼首席科学官（2014年7月至2016年10月）。1994年至2016年，他曾担任Millennium Sciences, Inc的首席执行官兼总裁。他也担任多种学术和临床职务，包括康奈尔大学威尔医学院（Weill College of Medicine, Cornell University）的临床泌尿和生殖医学教授（2009年至2016年）、Albert Einstein College of Medicine/Montefiore Medical Center的男性生殖中心主任（1998年至1999年），以及Columbia University、College of Physicians and Surgeons的临床泌尿外科教授（1999年至2009年）。2014年至2015年，他曾在霍华德斯特恩的sirius xm公司广播频道101举办The Dr. Harry Fisch Show。他是一个委员会认证的泌尿科医生，也是the American College of Surgeons的成员。他持有the State University of New York（位于宾厄姆顿）的化学学士学位、Mount Sinai School of Medicine（位于纽约）的医学博士学位，也曾在Albert Einstein College of Medicine/Montefiore Medical Center进行外科和泌尿道培训。
Harry Fisch, has served as a director of the Company since October 2016, as Vice Chairman of the Board since March 2018 and as Chief Corporate Officer of the Company since January 2018. Dr. Fisch was the co-founder of Aspen Park and served as the Chairman of the Board and Chief Scientific Officer of Aspen Park from July 2014 to October 2016. Since 1994, Dr. Fisch has served as the Chief Executive Officer and President of Millennium Sciences, Inc. Dr. Fisch has also had numerous academic and clinical appointments including Clinical Professor of Urology and Reproductive Medicine at Weill College of Medicine, Cornell University from 2009 to 2022, Director of the Male Reproductive Center at Albert Einstein College of Medicine/Montefiore Medical Center from 1998 to 1999 and Professor of Clinical Urology at Columbia University, College of Physicians and Surgeons from 1999 to 2009. Dr. Fisch is a Board Certified Urologist and a Fellow of the American College of Surgeons. Dr. Fisch holds a B.A. in Chemistry from the State University of New York at Binghamton, an M.D. from Mount Sinai School of Medicine, New York, and performed his surgical and urologic training at Albert Einstein College of Medicine/Montefiore Medical Center. - Harry Fisch，他是公司的董事（2016年10月以来）。他曾担任Aspen Park的联席创始人，也曾担任Aspen Park的董事会主席兼首席科学官（2014年7月至2016年10月）。1994年至2016年，他曾担任Millennium Sciences, Inc的首席执行官兼总裁。他也担任多种学术和临床职务，包括康奈尔大学威尔医学院（Weill College of Medicine, Cornell University）的临床泌尿和生殖医学教授（2009年至2016年）、Albert Einstein College of Medicine/Montefiore Medical Center的男性生殖中心主任（1998年至1999年），以及Columbia University、College of Physicians and Surgeons的临床泌尿外科教授（1999年至2009年）。2014年至2015年，他曾在霍华德斯特恩的sirius xm公司广播频道101举办The Dr. Harry Fisch Show。他是一个委员会认证的泌尿科医生，也是the American College of Surgeons的成员。他持有the State University of New York（位于宾厄姆顿）的化学学士学位、Mount Sinai School of Medicine（位于纽约）的医学博士学位，也曾在Albert Einstein College of Medicine/Montefiore Medical Center进行外科和泌尿道培训。
- Harry Fisch, has served as a director of the Company since October 2016, as Vice Chairman of the Board since March 2018 and as Chief Corporate Officer of the Company since January 2018. Dr. Fisch was the co-founder of Aspen Park and served as the Chairman of the Board and Chief Scientific Officer of Aspen Park from July 2014 to October 2016. Since 1994, Dr. Fisch has served as the Chief Executive Officer and President of Millennium Sciences, Inc. Dr. Fisch has also had numerous academic and clinical appointments including Clinical Professor of Urology and Reproductive Medicine at Weill College of Medicine, Cornell University from 2009 to 2022, Director of the Male Reproductive Center at Albert Einstein College of Medicine/Montefiore Medical Center from 1998 to 1999 and Professor of Clinical Urology at Columbia University, College of Physicians and Surgeons from 1999 to 2009. Dr. Fisch is a Board Certified Urologist and a Fellow of the American College of Surgeons. Dr. Fisch holds a B.A. in Chemistry from the State University of New York at Binghamton, an M.D. from Mount Sinai School of Medicine, New York, and performed his surgical and urologic training at Albert Einstein College of Medicine/Montefiore Medical Center.
- Michael L. Rankowitz
-
MichaelL.Rankowitz自2018年3月起担任公司董事。Rankowitz先生自2001年以来一直担任摩根士丹利的高级顾问。从1980年到2001年，Rankowitz先生是摩根士丹利的常务董事，在那里他还担任全球高收益的联席主管，负责高收益，新兴市场，银行债务和不良证券的风险管理，研究和销售。Rankowitz先生曾在NF Investment Corp.，Carlyle Funds，1st Tee of Metropolitan New York，Discover Card，Clarent Hospital Corp.，纽约赛马管理局，国际诵读困难症协会纽约分会，纽约三一学校和布朗宁学校（纽约）担任董事。他获有University of Vermont数学学士学位。
Michael L. Rankowitz, has served as a director of the Company since March 2018. Mr. Rankowitz has served as a Senior Advisor at Morgan Stanley since 2001. From 1980 to 2001, Mr. Rankowitz was employed at Morgan Stanely, most recently from 1992 to 2001 as a managing director, where he also served as a co-head of Global High Yield and was responsible for risk management, research and sales for high yield, emerging markets, bank debt and distressed securities. Mr. Rankowitz has held directorships with NF Investment Corp., Carlyle Funds, 1st Tee of Metropolitan New York, Discover Card, Clarent Hospital Corp., New York Racing Authority, International Dyslexia Association - New York Branch, Trinity School (New York) and Browning School (New York). He has a B.S. in Mathematics from the University of Vermont. - MichaelL.Rankowitz自2018年3月起担任公司董事。Rankowitz先生自2001年以来一直担任摩根士丹利的高级顾问。从1980年到2001年，Rankowitz先生是摩根士丹利的常务董事，在那里他还担任全球高收益的联席主管，负责高收益，新兴市场，银行债务和不良证券的风险管理，研究和销售。Rankowitz先生曾在NF Investment Corp.，Carlyle Funds，1st Tee of Metropolitan New York，Discover Card，Clarent Hospital Corp.，纽约赛马管理局，国际诵读困难症协会纽约分会，纽约三一学校和布朗宁学校（纽约）担任董事。他获有University of Vermont数学学士学位。
- Michael L. Rankowitz, has served as a director of the Company since March 2018. Mr. Rankowitz has served as a Senior Advisor at Morgan Stanley since 2001. From 1980 to 2001, Mr. Rankowitz was employed at Morgan Stanely, most recently from 1992 to 2001 as a managing director, where he also served as a co-head of Global High Yield and was responsible for risk management, research and sales for high yield, emerging markets, bank debt and distressed securities. Mr. Rankowitz has held directorships with NF Investment Corp., Carlyle Funds, 1st Tee of Metropolitan New York, Discover Card, Clarent Hospital Corp., New York Racing Authority, International Dyslexia Association - New York Branch, Trinity School (New York) and Browning School (New York). He has a B.S. in Mathematics from the University of Vermont.
- Grace Hyun
-
Grace Hyun自2020年8月起担任公司董事。炫女士自2017年以来一直担任布鲁克林NYU Langone Hospital的儿科泌尿外科主任，并担任NYU Langone医学院的临床副教授。Hyun女士于2011年至2017年担任西奈山医疗中心儿科泌尿外科副主任，并担任西奈山医学院助理教授。她曾担任the American Urological Association、the New York Academy of Medicine和the Society of Pediary Urology的纽约分部的董事会成员。她在康奈尔大学医学院（Cornell University Medical School）获得医学博士学位，在哥伦比亚大学（Columbia University）获得历史学士学位。
Grace Hyun,has served as a director of the Company since August 2020. Ms. Hyun has served as a Director of Pediatric Urology at NYU Langone Hospital-Brooklyn and a Clinical Associate Professor at NYU Langone School of Medicine since 2017. From 2011 to 2017, Ms. Hyun served as an Associate Director of Pediatric Urology at The Mount Sinai Medical Center and as an Assistant Professor at The Mount Sinai School of Medicine. She has served as a board member to the New York Section of the American Urological Association, the New York Academy of Medicine and the Societies of Pediatric Urology. She received her M.D. from Cornell University Medical School and has a B.A. in History from Columbia University. - Grace Hyun自2020年8月起担任公司董事。炫女士自2017年以来一直担任布鲁克林NYU Langone Hospital的儿科泌尿外科主任，并担任NYU Langone医学院的临床副教授。Hyun女士于2011年至2017年担任西奈山医疗中心儿科泌尿外科副主任，并担任西奈山医学院助理教授。她曾担任the American Urological Association、the New York Academy of Medicine和the Society of Pediary Urology的纽约分部的董事会成员。她在康奈尔大学医学院（Cornell University Medical School）获得医学博士学位，在哥伦比亚大学（Columbia University）获得历史学士学位。
- Grace Hyun,has served as a director of the Company since August 2020. Ms. Hyun has served as a Director of Pediatric Urology at NYU Langone Hospital-Brooklyn and a Clinical Associate Professor at NYU Langone School of Medicine since 2017. From 2011 to 2017, Ms. Hyun served as an Associate Director of Pediatric Urology at The Mount Sinai Medical Center and as an Assistant Professor at The Mount Sinai School of Medicine. She has served as a board member to the New York Section of the American Urological Association, the New York Academy of Medicine and the Societies of Pediatric Urology. She received her M.D. from Cornell University Medical School and has a B.A. in History from Columbia University.
- Mitchell S. Steiner
-
Mitchell S. Steiner，GTx的共同创始人，自公司于1997年注册成立起任首席执行官兼副董事长；目前在科学咨询委员会任职。1995年至2003年，他担任过许多学术职务，包括田纳西州大学的Urology的董事长兼教授，Urologic Oncology and Research的董事，Urologic Oncology的主席。他持有Vanderbilt University的分子生物学学士学位，田纳西州大学医学博士学位，及在 The Johns Hopkins Hospital完成其 surgery and urologic实习训练。他担任GTx的首席执行官，负责制定全面的产品开发及商业战略。
Mitchell S. Steiner, has served as President and Chief Executive Officer of the Company and as a director of the Company since October 2016 and as Chairman of the Board since March 2018. Dr. Steiner was the co-founder of Aspen Park Pharmaceuticals, Inc. ("Aspen Park"), and served as Aspen Park's Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NASDAQ:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men's health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine. - Mitchell S. Steiner，GTx的共同创始人，自公司于1997年注册成立起任首席执行官兼副董事长；目前在科学咨询委员会任职。1995年至2003年，他担任过许多学术职务，包括田纳西州大学的Urology的董事长兼教授，Urologic Oncology and Research的董事，Urologic Oncology的主席。他持有Vanderbilt University的分子生物学学士学位，田纳西州大学医学博士学位，及在 The Johns Hopkins Hospital完成其 surgery and urologic实习训练。他担任GTx的首席执行官，负责制定全面的产品开发及商业战略。
- Mitchell S. Steiner, has served as President and Chief Executive Officer of the Company and as a director of the Company since October 2016 and as Chairman of the Board since March 2018. Dr. Steiner was the co-founder of Aspen Park Pharmaceuticals, Inc. ("Aspen Park"), and served as Aspen Park's Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NASDAQ:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men's health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.
- Lucy Lu
-
Lucy Lu， 她是医学博士，曾担任执行副总裁和首席财务官（自2012年2月22日以来）。她有在医疗保健行业超过10年的经验。从2007年2月到2012年1月，她担任Citigroup Investment Research高级生物技术股票分析师。从2004年到加入花旗集团，她一直任职First Albany Capital，并于2004年4月担任副总裁，于2006年2月成为公司的负责人。她持有纽约大学医学院的医学博士学位，纽约大学医学院的的硕士学位，纽约大学斯特恩商学院的硕士学位。她获得Tennessee大学艺术和科学学院的学士学位。
Lucy Lu,has served as a director of the Company since May 2021 and previously from October 2016 to March 2019. Since April 2022, Dr. Lu has served as Chief Operations Officer of Innovative Cellular Therapeutics, Inc., a company focused on developing cell therapy for solid tumors. Since November 2022, Dr. Lu has served as a director of Inventiva S.A., a clinical stage biopharmaceutical company. From February 2015 to March 2022, Dr. Lu was President, Chief Executive Officer and a director of Avenue Therapeutics, Inc., a company focused on pharmaceutical therapies Veru Inc. ed in the acute care setting. From February 2012 to June 2017, Dr. Lu was the Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From February 2007 to January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of First Albany Capital in February 2006. Dr. Lu obtained her M.D. from the New York University School of Medicine and her M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science. - Lucy Lu， 她是医学博士，曾担任执行副总裁和首席财务官（自2012年2月22日以来）。她有在医疗保健行业超过10年的经验。从2007年2月到2012年1月，她担任Citigroup Investment Research高级生物技术股票分析师。从2004年到加入花旗集团，她一直任职First Albany Capital，并于2004年4月担任副总裁，于2006年2月成为公司的负责人。她持有纽约大学医学院的医学博士学位，纽约大学医学院的的硕士学位，纽约大学斯特恩商学院的硕士学位。她获得Tennessee大学艺术和科学学院的学士学位。
- Lucy Lu,has served as a director of the Company since May 2021 and previously from October 2016 to March 2019. Since April 2022, Dr. Lu has served as Chief Operations Officer of Innovative Cellular Therapeutics, Inc., a company focused on developing cell therapy for solid tumors. Since November 2022, Dr. Lu has served as a director of Inventiva S.A., a clinical stage biopharmaceutical company. From February 2015 to March 2022, Dr. Lu was President, Chief Executive Officer and a director of Avenue Therapeutics, Inc., a company focused on pharmaceutical therapies Veru Inc. ed in the acute care setting. From February 2012 to June 2017, Dr. Lu was the Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From February 2007 to January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of First Albany Capital in February 2006. Dr. Lu obtained her M.D. from the New York University School of Medicine and her M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science.
高管简历
中英对照 | 中文 | 英文- Harry Fisch
Harry Fisch，他是公司的董事（2016年10月以来）。他曾担任Aspen Park的联席创始人，也曾担任Aspen Park的董事会主席兼首席科学官（2014年7月至2016年10月）。1994年至2016年，他曾担任Millennium Sciences, Inc的首席执行官兼总裁。他也担任多种学术和临床职务，包括康奈尔大学威尔医学院（Weill College of Medicine, Cornell University）的临床泌尿和生殖医学教授（2009年至2016年）、Albert Einstein College of Medicine/Montefiore Medical Center的男性生殖中心主任（1998年至1999年），以及Columbia University、College of Physicians and Surgeons的临床泌尿外科教授（1999年至2009年）。2014年至2015年，他曾在霍华德斯特恩的sirius xm公司广播频道101举办The Dr. Harry Fisch Show。他是一个委员会认证的泌尿科医生，也是the American College of Surgeons的成员。他持有the State University of New York（位于宾厄姆顿）的化学学士学位、Mount Sinai School of Medicine（位于纽约）的医学博士学位，也曾在Albert Einstein College of Medicine/Montefiore Medical Center进行外科和泌尿道培训。
Harry Fisch, has served as a director of the Company since October 2016, as Vice Chairman of the Board since March 2018 and as Chief Corporate Officer of the Company since January 2018. Dr. Fisch was the co-founder of Aspen Park and served as the Chairman of the Board and Chief Scientific Officer of Aspen Park from July 2014 to October 2016. Since 1994, Dr. Fisch has served as the Chief Executive Officer and President of Millennium Sciences, Inc. Dr. Fisch has also had numerous academic and clinical appointments including Clinical Professor of Urology and Reproductive Medicine at Weill College of Medicine, Cornell University from 2009 to 2022, Director of the Male Reproductive Center at Albert Einstein College of Medicine/Montefiore Medical Center from 1998 to 1999 and Professor of Clinical Urology at Columbia University, College of Physicians and Surgeons from 1999 to 2009. Dr. Fisch is a Board Certified Urologist and a Fellow of the American College of Surgeons. Dr. Fisch holds a B.A. in Chemistry from the State University of New York at Binghamton, an M.D. from Mount Sinai School of Medicine, New York, and performed his surgical and urologic training at Albert Einstein College of Medicine/Montefiore Medical Center.- Harry Fisch，他是公司的董事（2016年10月以来）。他曾担任Aspen Park的联席创始人，也曾担任Aspen Park的董事会主席兼首席科学官（2014年7月至2016年10月）。1994年至2016年，他曾担任Millennium Sciences, Inc的首席执行官兼总裁。他也担任多种学术和临床职务，包括康奈尔大学威尔医学院（Weill College of Medicine, Cornell University）的临床泌尿和生殖医学教授（2009年至2016年）、Albert Einstein College of Medicine/Montefiore Medical Center的男性生殖中心主任（1998年至1999年），以及Columbia University、College of Physicians and Surgeons的临床泌尿外科教授（1999年至2009年）。2014年至2015年，他曾在霍华德斯特恩的sirius xm公司广播频道101举办The Dr. Harry Fisch Show。他是一个委员会认证的泌尿科医生，也是the American College of Surgeons的成员。他持有the State University of New York（位于宾厄姆顿）的化学学士学位、Mount Sinai School of Medicine（位于纽约）的医学博士学位，也曾在Albert Einstein College of Medicine/Montefiore Medical Center进行外科和泌尿道培训。
- Harry Fisch, has served as a director of the Company since October 2016, as Vice Chairman of the Board since March 2018 and as Chief Corporate Officer of the Company since January 2018. Dr. Fisch was the co-founder of Aspen Park and served as the Chairman of the Board and Chief Scientific Officer of Aspen Park from July 2014 to October 2016. Since 1994, Dr. Fisch has served as the Chief Executive Officer and President of Millennium Sciences, Inc. Dr. Fisch has also had numerous academic and clinical appointments including Clinical Professor of Urology and Reproductive Medicine at Weill College of Medicine, Cornell University from 2009 to 2022, Director of the Male Reproductive Center at Albert Einstein College of Medicine/Montefiore Medical Center from 1998 to 1999 and Professor of Clinical Urology at Columbia University, College of Physicians and Surgeons from 1999 to 2009. Dr. Fisch is a Board Certified Urologist and a Fellow of the American College of Surgeons. Dr. Fisch holds a B.A. in Chemistry from the State University of New York at Binghamton, an M.D. from Mount Sinai School of Medicine, New York, and performed his surgical and urologic training at Albert Einstein College of Medicine/Montefiore Medical Center.
- K. Gary Barnette
K.Gary Barnette自2018年9月起担任公司首席科学官。Barnette博士曾担任卡玛戈制药服务公司（Camargo Pharmaceutical Services“；Camargo”；）的科学和法规事务高级副总裁，该公司是一家专门从事505（b）（2）批准途径的药物开发服务提供商，2016年10月至2018年9月，担任Camargo科学和监管事务Vice President，2016年1月至2016年10月，担任Camargo药物开发Vice President，2012年5月至2016年1月。他也曾担任GTX公司（男性健康和肿瘤上市公司）的联席创始人，在那里他曾担任多种职务（从2001年到2012年）。Barnette从1998年到2001年在Solvay Pharmaceuticals，Inc.任职，最终担任监管事务主管。从1995年到1998年，Barnette博士担任美国食品和药物管理局（U.S.Food and Drug Administration）的临床药理学与生物制药审查员。Barnette博士于1995年在西弗吉尼亚大学（West Virginia University）获得基础药物科学哲学博士学位，并于1989年在塞勒姆学院（Salem College）获得理学学士学位。
K. Gary Barnette,has served as Chief Scientific Officer of the Company since September 2018. Dr. Barnette served as Senior Vice President of Scientific and Regulatory Affairs of Camargo Pharmaceutical Services ("Camargo"), now part of Premier Research, a provider of drug development services specializing in the 505(b)(2) approval pathway, from October 2016 to September 2018, as Vice President of Scientific and Regulatory Affairs of Camargo from January 2016 to October 2016, and as Vice President of Drug Development of Camargo from May 2012 to January 2016. Dr. Barnette was also the co-founder of GTx, Inc., a men's health and oncology public company, where he served in various roles from 2001 to 2012. From 1998 to 2001, Dr. Barnette worked for Solvay Pharmaceuticals, Inc., eventually serving as Director of Regulatory Affairs. From 1995 until 1998, Dr. Barnette served as Clinical Pharmacology and Biopharmaceutics Reviewer for the U.S. Food and Drug Administration. Dr. Barnette earned his Doctor of Philosophy, Basic Pharmaceutical Sciences from West Virginia University in 1995 and his Bachelor of Science from Salem College in 1989.- K.Gary Barnette自2018年9月起担任公司首席科学官。Barnette博士曾担任卡玛戈制药服务公司（Camargo Pharmaceutical Services“；Camargo”；）的科学和法规事务高级副总裁，该公司是一家专门从事505（b）（2）批准途径的药物开发服务提供商，2016年10月至2018年9月，担任Camargo科学和监管事务Vice President，2016年1月至2016年10月，担任Camargo药物开发Vice President，2012年5月至2016年1月。他也曾担任GTX公司（男性健康和肿瘤上市公司）的联席创始人，在那里他曾担任多种职务（从2001年到2012年）。Barnette从1998年到2001年在Solvay Pharmaceuticals，Inc.任职，最终担任监管事务主管。从1995年到1998年，Barnette博士担任美国食品和药物管理局（U.S.Food and Drug Administration）的临床药理学与生物制药审查员。Barnette博士于1995年在西弗吉尼亚大学（West Virginia University）获得基础药物科学哲学博士学位，并于1989年在塞勒姆学院（Salem College）获得理学学士学位。
- K. Gary Barnette,has served as Chief Scientific Officer of the Company since September 2018. Dr. Barnette served as Senior Vice President of Scientific and Regulatory Affairs of Camargo Pharmaceutical Services ("Camargo"), now part of Premier Research, a provider of drug development services specializing in the 505(b)(2) approval pathway, from October 2016 to September 2018, as Vice President of Scientific and Regulatory Affairs of Camargo from January 2016 to October 2016, and as Vice President of Drug Development of Camargo from May 2012 to January 2016. Dr. Barnette was also the co-founder of GTx, Inc., a men's health and oncology public company, where he served in various roles from 2001 to 2012. From 1998 to 2001, Dr. Barnette worked for Solvay Pharmaceuticals, Inc., eventually serving as Director of Regulatory Affairs. From 1995 until 1998, Dr. Barnette served as Clinical Pharmacology and Biopharmaceutics Reviewer for the U.S. Food and Drug Administration. Dr. Barnette earned his Doctor of Philosophy, Basic Pharmaceutical Sciences from West Virginia University in 1995 and his Bachelor of Science from Salem College in 1989.
- Mitchell S. Steiner
Mitchell S. Steiner，GTx的共同创始人，自公司于1997年注册成立起任首席执行官兼副董事长；目前在科学咨询委员会任职。1995年至2003年，他担任过许多学术职务，包括田纳西州大学的Urology的董事长兼教授，Urologic Oncology and Research的董事，Urologic Oncology的主席。他持有Vanderbilt University的分子生物学学士学位，田纳西州大学医学博士学位，及在 The Johns Hopkins Hospital完成其 surgery and urologic实习训练。他担任GTx的首席执行官，负责制定全面的产品开发及商业战略。
Mitchell S. Steiner, has served as President and Chief Executive Officer of the Company and as a director of the Company since October 2016 and as Chairman of the Board since March 2018. Dr. Steiner was the co-founder of Aspen Park Pharmaceuticals, Inc. ("Aspen Park"), and served as Aspen Park's Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NASDAQ:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men's health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.- Mitchell S. Steiner，GTx的共同创始人，自公司于1997年注册成立起任首席执行官兼副董事长；目前在科学咨询委员会任职。1995年至2003年，他担任过许多学术职务，包括田纳西州大学的Urology的董事长兼教授，Urologic Oncology and Research的董事，Urologic Oncology的主席。他持有Vanderbilt University的分子生物学学士学位，田纳西州大学医学博士学位，及在 The Johns Hopkins Hospital完成其 surgery and urologic实习训练。他担任GTx的首席执行官，负责制定全面的产品开发及商业战略。
- Mitchell S. Steiner, has served as President and Chief Executive Officer of the Company and as a director of the Company since October 2016 and as Chairman of the Board since March 2018. Dr. Steiner was the co-founder of Aspen Park Pharmaceuticals, Inc. ("Aspen Park"), and served as Aspen Park's Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NASDAQ:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men's health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.
- Michele Greco
Michele Greco,Ms. Greco 自2013年1月担任公司的副总裁何首席金融官。Ms. Greco是注册会计师，在Ernst & Young有限公司有公共审计超过30年的经验。2011年1月至2012年2月Ms. Greco在Systems Research公司提供顾问服务，担任金融专业 招聘人员。2009年3月至2011年1月Ms. Greco涉及私有企业。1994年至2009年3月Ms. Greco在Ernst & Young有限公司担任审计合作人，1981年加入Ernst & Young 有限公司。
Michele Greco,has served as Chief Financial Officer of the Company since March 2018 and as Chief Administrative Officer of the Company since December 2017. Ms. Greco served as Executive Vice President of Finance of the Company from October 2016 to March 2018, as Executive Vice President and Chief Financial Officer of the Company from December 2014 to October 2016 and as Vice President and Chief Financial Officer of the Company from January 2013 to December 2014. Ms. Greco is a CPA with nearly 30 years of experience in public accounting with Ernst & Young LLP. From January 2011 to February 2012, Ms. Greco provided consulting services to Systems Research Incorporated as a recruiter of finance professionals. From March 2009 to January 2011, Ms. Greco was involved in a series of personal business ventures. From 1994 to March 2009, Ms. Greco served as an audit partner with Ernst & Young LLP. Ms. Greco joined Ernst & Young LLP in 1981.- Michele Greco,Ms. Greco 自2013年1月担任公司的副总裁何首席金融官。Ms. Greco是注册会计师，在Ernst & Young有限公司有公共审计超过30年的经验。2011年1月至2012年2月Ms. Greco在Systems Research公司提供顾问服务，担任金融专业 招聘人员。2009年3月至2011年1月Ms. Greco涉及私有企业。1994年至2009年3月Ms. Greco在Ernst & Young有限公司担任审计合作人，1981年加入Ernst & Young 有限公司。
- Michele Greco,has served as Chief Financial Officer of the Company since March 2018 and as Chief Administrative Officer of the Company since December 2017. Ms. Greco served as Executive Vice President of Finance of the Company from October 2016 to March 2018, as Executive Vice President and Chief Financial Officer of the Company from December 2014 to October 2016 and as Vice President and Chief Financial Officer of the Company from January 2013 to December 2014. Ms. Greco is a CPA with nearly 30 years of experience in public accounting with Ernst & Young LLP. From January 2011 to February 2012, Ms. Greco provided consulting services to Systems Research Incorporated as a recruiter of finance professionals. From March 2009 to January 2011, Ms. Greco was involved in a series of personal business ventures. From 1994 to March 2009, Ms. Greco served as an audit partner with Ernst & Young LLP. Ms. Greco joined Ernst & Young LLP in 1981.